Leiden University Medical Center, Department of Gynecology, Leiden, The Netherlands.
PLoS One. 2013 Jul 9;8(7):e67414. doi: 10.1371/journal.pone.0067414. Print 2013.
Treatment choices for cervical cancer are primarily based on clinical FIGO stage and the post-operative evaluation of prognostic parameters including tumor diameter, parametrial and lymph node involvement, vaso-invasion, infiltration depth, and histological type. The aim of this study was to evaluate genomic changes in bulky cervical tumors and their relation to clinical parameters, using single nucleotide polymorphism (SNP)-analysis. Flow-sorted tumor cells and patient-matched normal cells were extracted from 81 bulky cervical tumors. DNA-index (DI) measurement and whole genome SNP-analysis were performed. Data were analyzed to detect copy number alterations (CNA) and allelic balance state: balanced, imbalanced or pure LOH, and their relation to clinical parameters. The DI varied from 0.92-2.56. Pure LOH was found in ≥40% of samples on chromosome-arms 3p, 4p, 6p, 6q, and 11q, CN gains in >20% on 1q, 3q, 5p, 8q, and 20q, and losses on 2q, 3p, 4p, 11q, and 13q. Over 40% showed gain on 3q. The only significant differences were found between histological types (squamous, adeno and adenosquamous) in the lesser allele intensity ratio (LAIR) (p = 0.035) and in the CNA analysis (p = 0.011). More losses were found on chromosome-arm 2q (FDR = 0.004) in squamous tumors and more gains on 7p, 7q, and 9p in adenosquamous tumors (FDR = 0.006, FDR = 0.004, and FDR = 0.029). Whole genome analysis of bulky cervical cancer shows widespread changes in allelic balance and CN. The overall genetic changes and CNA on specific chromosome-arms differed between histological types. No relation was found with the clinical parameters that currently dictate treatment choice.
宫颈癌的治疗选择主要基于临床 FIGO 分期和术后预后参数的评估,包括肿瘤直径、宫旁和淋巴结受累、血管侵犯、浸润深度和组织学类型。本研究旨在使用单核苷酸多态性(SNP)分析评估大体积宫颈癌中的基因组变化及其与临床参数的关系。从 81 例大体积宫颈癌中提取了流式分选的肿瘤细胞和患者匹配的正常细胞。进行了 DNA 指数(DI)测量和全基因组 SNP 分析。分析数据以检测拷贝数改变(CNA)和等位基因平衡状态:平衡、不平衡或纯 LOH,并分析其与临床参数的关系。DI 从 0.92-2.56 不等。≥40%的样本在染色体臂 3p、4p、6p、6q 和 11q 上发现纯 LOH,>20%的样本在 1q、3q、5p、8q 和 20q 上发现 CN 增益,而在 2q、3p、4p、11q 和 13q 上发现缺失。超过 40%的样本在 3q 上出现增益。仅在组织学类型(鳞癌、腺癌和腺鳞癌)之间发现较小等位基因强度比(LAIR)(p=0.035)和 CNA 分析(p=0.011)存在显著差异。在鳞癌中,2q 染色体臂上发现更多缺失(FDR=0.004),在腺鳞癌中,7p、7q 和 9p 上发现更多增益(FDR=0.006、FDR=0.004 和 FDR=0.029)。大体积宫颈癌的全基因组分析显示,等位基因平衡和 CN 广泛改变。不同组织学类型之间的总体遗传变化和特定染色体臂上的 CNA 不同。与目前决定治疗选择的临床参数之间没有关系。